- Home
- CYRX vs MNPR Comparison
CYRX vs MNPR Comparison
Compare CYRX & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYRX | MNPR |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.6M | 372.9M |
| IPO Year | 2008 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CYRX | MNPR |
|---|---|---|
| Price | $8.05 | $56.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $12.94 | ★ $101.42 |
| AVG Volume (30 Days) | ★ 341.9K | 182.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $176,177,000.00 | N/A |
| Revenue This Year | $9.71 | N/A |
| Revenue Next Year | $9.56 | N/A |
| P/E Ratio | $4.99 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.63 | $26.06 |
| 52 Week High | $11.45 | $105.00 |
Technical Indicators
Market Signals| Indicator | CYRX | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 37.26 | 46.94 |
| Support Level | $6.57 | $56.15 |
| Resistance Level | $8.45 | $61.30 |
| Average True Range (ATR) | 0.51 | 3.47 |
| MACD | 0.04 | 0.56 |
| Stochastic Oscillator | 25.71 | 59.08 |
Price Performance
Historical ComparisonAbout CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.